BNP Paribas Financial Markets’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-395
| Closed | -$2.31K | – | 4128 |
|
|
2022
Q4 | $2.31K | Sell |
395
-10,667
| -96% | -$56.1K | ﹤0.01% | 3728 |
|
|
2022
Q3 | $74.1K | Buy |
11,062
+10,946
| +9,436% | +$66.4K | ﹤0.01% | 3879 |
|
|
2022
Q2 | $488 | Buy |
116
+8
| +7% | +$32 | ﹤0.01% | 3951 |
|
|
2022
Q1 | $364 | Sell |
108
-24,426
| -100% | -$77.4K | ﹤0.01% | 4047 |
|
|
2021
Q4 | $77.3K | Buy |
24,534
+24,426
| +22,617% | +$81.3K | ﹤0.01% | 3660 |
|
|
2021
Q3 | $353 | Buy |
108
+11
| +11% | +$39 | ﹤0.01% | 3936 |
|
|
2021
Q2 | $409 | Sell |
97
-10,900
| -99% | -$46.1K | ﹤0.01% | 3984 |
|
|
2021
Q1 | $54.9K | Buy |
10,997
+5,259
| +92% | +$42.5K | ﹤0.01% | 3589 |
|
|
2020
Q4 | $72.5K | Sell |
5,738
-1,002
| -15% | -$11.4K | ﹤0.01% | 3375 |
|
|
2020
Q3 | $66.2K | Buy |
6,740
+5,505
| +446% | +$54.2K | ﹤0.01% | 3327 |
|
|
2020
Q2 | $12.3K | Sell |
1,235
-6,881
| -85% | -$66K | ﹤0.01% | 3615 |
|
|
2020
Q1 | $71.7K | Buy |
8,116
+2,904
| +56% | +$28.6K | ﹤0.01% | 3375 |
|
|
2019
Q4 | $48.1K | Buy |
5,212
+1,790
| +52% | +$12.7K | ﹤0.01% | 3668 |
|
|
2019
Q3 | $20.1K | Buy |
3,422
+1,049
| +44% | +$11.1K | ﹤0.01% | 3947 |
|
|
2019
Q2 | $28.5K | Sell |
2,373
-2,058
| -46% | -$22.1K | ﹤0.01% | 3754 |
|
|
2019
Q1 | $53.5K | Buy |
4,431
+4,424
| +63,200% | +$65.2K | ﹤0.01% | 3463 |
|
|
2018
Q4 | $88 | Sell |
7
-689
| -99% | -$9.51K | ﹤0.01% | 4203 |
|
|
2018
Q3 | $10.3K | Hold |
696
| – | – | ﹤0.01% | 3714 |
|
|
2018
Q2 | $11.7K | Sell |
696
-3,065
| -81% | -$59.5K | ﹤0.01% | 3714 |
|
|
2018
Q1 | $86.1K | Buy |
3,761
+39
| +1% | +$867 | ﹤0.01% | 3267 |
|
|
2017
Q4 | $96.3K | Buy |
3,722
+2,043
| +122% | +$41.1K | ﹤0.01% | 3324 |
|
|
2017
Q3 | $24.8K | Sell |
1,679
-131
| -7% | -$1.9K | ﹤0.01% | 3488 |
|
|
2017
Q2 | $25.3K | Buy |
1,810
+1,778
| +5,556% | +$26.2K | ﹤0.01% | 3528 |
|
|
2017
Q1 | $546 | Sell |
32
-257
| -89% | -$3.08K | ﹤0.01% | 3832 |
|
|
2016
Q4 | $2.97K | Sell |
289
-933
| -76% | -$8.53K | ﹤0.01% | 3850 |
|
|
2016
Q3 | $12.4K | Buy |
1,222
+578
| +90% | +$6.32K | ﹤0.01% | 3111 |
|
|
2016
Q2 | $7.23K | Buy |
644
+570
| +770% | +$7.26K | ﹤0.01% | 3077 |
|
|
2016
Q1 | $1.01K | Sell |
74
-2,780
| -97% | -$40K | ﹤0.01% | 2507 |
|
|
2015
Q4 | $54.1K | Sell |
2,854
-327
| -10% | -$7.11K | ﹤0.01% | 2758 |
|
|
2015
Q3 | $59.7K | Buy |
3,181
+1,901
| +149% | +$32.3K | ﹤0.01% | 2728 |
|
|
2015
Q2 | $19.1K | Buy |
+1,280
| New | +$19.5K | ﹤0.01% | 3081 |
|
|
2014
Q3 | – | Sell |
-69
| Closed | -$697 | – | 4328 |
|
|
2014
Q2 | $697 | Buy |
+69
| New | +$666 | ﹤0.01% | 3524 |
|
BNP Paribas Financial Markets's CNCE Position: Q1 2023 in Review
BNP Paribas Financial Markets sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 395 shares — an estimated $2.31K sold.
BNP Paribas Financial Markets first reported a position in CNCE in Q2 2014 and held it in 32 quarters. The position peaked at $96.3K in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- BNP Paribas Financial Markets reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- BNP Paribas Financial Markets sold 395 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.31K.
- BNP Paribas Financial Markets first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 32 quarters.
- BNP Paribas Financial Markets's Concert Pharmaceuticals, Inc. position peaked at $96.3K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2023, filed 12 May 2023.